Cargando…

Antiplatelet Therapy for Every Diabetic Person?

Detalles Bibliográficos
Autores principales:	Nicolucci, Antonio, Standl, Eberhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Diabetes and Cardiovascular Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632153/ https://www.ncbi.nlm.nih.gov/pubmed/21525447 http://dx.doi.org/10.2337/dc11-s210

Ejemplares similares

The Munich Myocardial Infarction Registry: Translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, pre-diabetes, and cardiovascular disease into clinical practice
por: Schnell, Oliver, et al.
Publicado: (2009)

Postprandial Hyperglycemia and Glycemic Variability: Should we care?
por: Standl, Eberhard, et al.
Publicado: (2011)

Heart in Diabetes: A Microvascular Disease
por: Laakso, Markku
Publicado: (2011)

Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines
por: Gallwitz, Baptist
Publicado: (2009)

Heart in Diabetes: Not Only a Macrovascular Disease
por: Stratmann, Bernd, et al.
Publicado: (2011)

Getting to the “Heart” of the Matter on Diabetic Cardiovascular Disease: “Thanks for the Memory”
por: Cefalu, William T., et al.
Publicado: (2016)

Should C-Reactive Protein Be a Target of Therapy?
por: Oh, Jisun, et al.
Publicado: (2011)

Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
por: Gori, Mauro, et al.
Publicado: (2016)

Is Hyperglycemia a Cardiovascular Risk Factor?
por: Pistrosch, Frank, et al.
Publicado: (2011)

Hypoglycemia and Cardiovascular Risks
por: Frier, Brian M., et al.
Publicado: (2011)

Shifting the Disease Management Paradigm From Glucose: What are the pros?
por: Stirban, Alin, et al.
Publicado: (2009)

Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease
por: Versari, Daniele, et al.
Publicado: (2009)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes
por: Bianchi, Cristina, et al.
Publicado: (2009)

Glucose Control and Cardiovascular Disease: Is it important? No
por: Conget, Ignacio, et al.
Publicado: (2009)

A Summary of the ADVANCE Trial
por: Heller, Simon R.
Publicado: (2009)

Is Hyperglycemia a Causal Factor in Cardiovascular Disease?: Does proving this relationship really matter? Yes
por: Davidson, Jaime A., et al.
Publicado: (2009)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
por: Kassem, Sameer A., et al.
Publicado: (2009)

Shifting the Disease Management Paradigm From Glucose: What are the cons?
por: Hanefeld, Markolf, et al.
Publicado: (2009)

The Role of Antiplatelet Therapy in Patients With MINOCA
por: Ortega-Paz, Luis, et al.
Publicado: (2022)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

Dual Antiplatelet Therapy vs. Single Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: An Updated Systematic Review and Meta-Analysis
por: Zhang, Yipeng, et al.
Publicado: (2021)

Body indices and basic vital signs in Helicobacter pylori positive and negative persons
por: Kopáčová, Marcela, et al.
Publicado: (2006)

Incidence of bleeding in patients on different anticoagulants and antiplatelet therapies undergoing thoracentesis
por: Aljundi, Lamia, et al.
Publicado: (2021)

Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing
por: Ostrowska, Małgorzata, et al.
Publicado: (2019)

Uncovering Pathways to Personalized Therapies in Type 1 Diabetes
por: Linsley, Peter S., et al.
Publicado: (2021)

Should 24-h Ambulatory Blood Pressure Monitoring Be Done in Every Patient With Diabetes?
por: Parati, Gianfranco, et al.
Publicado: (2009)

Duration of Dual Antiplatelet Therapy After Implantation of Drug-Coated Balloon
por: Zhang, Yuxuan, et al.
Publicado: (2021)

Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial
por: Shi, Xiujin, et al.
Publicado: (2021)

Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy
por: Karanasos, Antonios, et al.
Publicado: (2014)

Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
por: Jourdi, Georges, et al.
Publicado: (2022)

De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?
por: Galli, Mattia, et al.
Publicado: (2022)

Editorial: The individualization of antiplatelet therapy in coronary artery disease: escalation or de-escalations
por: Lee, Sang Yeub, et al.
Publicado: (2023)

Antiplatelet drugs and the perioperative period: What every urologist needs to know
por: Vasudeva, Pawan, et al.
Publicado: (2009)

Cardiovascular risk and protective factors in adults with and without diabetes mellitus (Italy, 2016–19)
por: Baldissera, Sandro, et al.
Publicado: (2022)

Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study
por: Crawford, Stephen O, et al.
Publicado: (2010)

Optimal Strategy for Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation in High-Risk “TWILIGHT-like” Patients With Diabetes Mellitus
por: Wang, Hao-Yu, et al.
Publicado: (2020)

Prolonged dual antiplatelet therapy after drug-eluting stent implantation in patients with diabetes mellitus: A nationwide retrospective cohort study
por: Lee, Seung-Jun, et al.
Publicado: (2022)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
por: Elliott, Jesse, et al.
Publicado: (2019)

Causal Relationship of Coronary Artery Calcium on Myocardial Infarction and Preventive Effect of Antiplatelet Therapy
por: Limpijankit, Thosaphol, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f2oml74r1h2nnchf8vin7vsepc